Malignant eye tumors are both rare and diverse, presenting unique diagnostic challenges. These conditions are not only harmful to eyesight but can also be life-threatening. Alfa Cytology is a world leader in the research of cancer. With our extensive experience and advanced platform, we can provide the best solutions for eye cancer.
Introduction to Eye Cancer
Cancer can also sometimes develop in the tissues around the eyeball or spread to the eye from other parts of the body, such as the lungs or breasts. Many different types of cancer can affect the eye. Ocular melanoma is the most common primary intraocular malignancy in adults, with approximately 2,500 cases diagnosed annually in the United States.
- Squamous cell carcinoma
- Retinoblastoma - a childhood cancer
Fig.1 Schematic diagram of the anatomy of the eye. (Lorenzo-Veiga, B., et al., 2021)
Therapy Development for Eye Cancer
The exact cause of eye cancer is often unknown, but some risk factors have been identified, including genetic factors, age, exposure to ultraviolet (UV) light, and immunosuppression. The common therapy for eye cancer involves radiation therapy, laser therapy, and chemotherapy. New therapies for eye cancer are also constantly evolving, such as chimeric antigen receptor (CAR) T-cell therapy. In addition, Aura Biosciences is developing viral nanoparticle complexes (VNCs) for ocular melanoma therapy.
Fig.2 Strategies for the application of stem cell therapy in eye cancer. (Chu, D.T., et al., 2020)
Our Services
Eye cancer includes various types of malignant tumors that affect different structures of the eye. Advances in therapies, the cancer epitopes or targets identification, understanding of cancer mechanisms or causes, and ongoing research and development efforts are critical to diagnosis, improving outcomes, and providing better therapy options. Therefore, Alfa Cytology is working on providing one-stop solutions for eye cancer, including but not limited to the following.
Alfa Cytology is committed to the research and study of cancer, from molecular biology services, and cancer biomarker discovery services, to preclinical research services, providing one-stop services. Our cancer experts have many years of experience in the development of the latest therapies for eye cancer. If you are interested in our service, please contact us.
References
- Lorenzo-Veiga, B., et al.; (2021). Age-related ocular conditions: Current treatments and role of cyclodextrin-based nanotherapies. International Journal of Pharmaceutics, 603, 120707. doi:10.1016/j.ijpharm.2021.120707
- Chu, D.T., et al.; (2020) Recent Progress of Stem Cell Therapy in Cancer Treatment: Molecular Mechanisms and Potential Applications. Cells, 9, 563. https://doi.org/10.3390/cells9030563
For research use only.
Related Services
